Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SymBio Initiates Japanese Phase II Trial for TREAKISYM®

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Company has commenced enrollment for bendamustine in CLL patients.

SymBio Pharmaceuticals Limited has announced that it has commenced enrollment in a Phase 2 clinical trial in Japan for bendamustine hydrochloride (Brand Name: TREAKISYM®) in chronic lymphocytic leukemia (CLL) patients.

In partnership with Eisai Co., Ltd., SymBio received marketing approval for TREAKISYM® (SyB L-0501) in October, 2010, to treat Japanese patients with relapsed/refractory (r/r) low-grade non-Hodgkin’s lymphoma (LG-NHL) and mantle cell lymphoma (MCL).

CLL is a cancer of the blood characterized by the progressive accumulation of functionally incompetent lymphocytes, a type of white blood cell produced by the bone marrow and organs of the lymphatic system.

The number of CLL patients in Japan is estimated to be around 2,000. In the US and EU, bendamustine has been approved for the treatment of CLL where the disease accounts for an estimated 30% of all leukemia cases.

Due to the lack of effective therapies in Japan, CLL patients are seriously underserved and a high unmet medical need exists for the development of an effective alternative therapy.

In Japan, the Ministry of Health, Labour and Welfare (MHLW) Working Group has designated TREAKISYM® as a prioritized unapproved drug having high potential to address the lack of an effective therapy in CLL. TREAKISYM® was designated by MHLW as an orphan drug for the CLL indication in June, 2012.

SymBio has initiated several phase 2 trials for SyB L-0501. The Company continues to pursue other indications for TREAKISYM® in the hematology space as nimbly as possible in order to maximize the potential of TREAKISYM® and address other high unmet medical needs in patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!